Indian Patent Office | Intellepedia

Roche’s backbone rendered brittle by Indian Patent Office

The Indian Patent Office has revoked Roche’s patent on Bonviva after Cipla challenged its validity, citing a lack of inventive step and patentability. This decision highlights critical aspects of Indian pharmaceutical patent law and its impact on international drug companies.

Drug Humira turns Rheumatic for Abbott Biotechnology

The Indian Patent Office set aside Abbott Biotechnology’s Humira patent after Glenmark’s pre-grant opposition, citing lack of inventive step and insufficient disclosure. This legal dispute underscores ongoing challenges to Humira patents both in India and globally.

Elucidating the Patent Process – Part 1

This post describes the different types of patent applications available under Indian law and their essential procedural requirements. It provides clarity on the patent process in India, focusing on application types, filing priorities, and statutory conditions.

Patent e-filing Amendment

The Indian Patent Office has implemented significant upgrades to its electronic patent filing system, incorporating broader e-filing capabilities and changes under the Patents Amendment Rules 2014. These amendments affect processes for assignments, certified copies, and administrative requests, enhancing efficiency for stakeholders.